Adjuvant treatment with osimertinib in patients with stage IB-IIIA EGFR-positive NSCLC after complete tumor resection reduces the risk of relapse and death by 83%

Best Practice Nordic | Jun 2020 | ASCO20 Virtual |

Osimertinib is a tyrosine kinase inhibitor that inhibits both activating EGFR mutations and the EGFR T790M resistance mutation. The question is whether osimertinib can be used at an earlier stage of the disease in a patient group, where the majority is getting progression and frequent central nervous system metastases. The ADAURA study has evaluated osimertinib as adjuvant therapy in patients with stage IB to IIIA EGFR mutation-positive non-small cell lung cancer after complete resection. The results was presented by Roy Herbst, associate director for Translational Research at Yale Cancer Center in New Haven, Connecticut at this years ASCO congress. The multinational randomized phase III study with 682 patients with primary non-small cell lung stage IB-IIIA and EGFR mutation showed an 83% risk reduction for relapse and death for this group of patients despite surgery and chemotherapy. A finding that according to Richard L. Schilsky, ASCO Chief Medical Officer and Executive Vice President, shows that data strongly supports the use of targeted treatment with Osimertinib at an earlier stage of the disease. In addition, the study found that 90% of patients treated with osimertinib achieved disease-free survival after two years compared to 44% in the control group. Read the English abstract published on Asco here.